AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ionis Pharmaceuticals shares rise 4.94% intraday after reporting strong Q2 earnings and revenue growth.
ByAinvest
Wednesday, Jul 30, 2025 1:27 pm ET1min read
Ionis Pharmaceuticals, Inc. rose 4.94% intraday, with the company reporting strong second-quarter earnings results. Revenue increased to USD 452 million from USD 225 million a year ago, and net income turned to a profit of USD 124 million from a net loss of USD 66 million. The company also expects additional advancements in the second half of the year, including the launch of donidalorsen for hereditary angioedema and important Phase 3 results for olezarsen in severe hypertriglyceridemia and zilganersen.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet